Información del artículo
Abstract
Introduction
Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
ObjectiveTo provide a review and update of the pharmacological and therapeutic characteristics of natalizumab, with special emphasis on the most recently published data on the efficacy, effectiveness and safety of this drug.
DevelopmentSeveral randomized clinical trials in patients with relapsing forms of multiple sclerosis have demonstrated that natalizumab substantially reduces clinical and radiological disease activity. Post hoc analysis of phase III clinical trials and the results of post-approval observational studies indicate that natalizumab significantly increases the proportion of patients with complete clinical and radiological response and is effective in patients with highly active forms of multiple sclerosis and suboptimal response to other treatments. Like other monoclonal antibodies, natalizumab can cause hypersensitivity reactions, which are severe in 1% of patients. Other adverse effects are generally mild or infrequent. Nevertheless, several cases of progressive multifocal leukoencephalopathy have been detected in patients treated with natalizumab monotherapy. The risk of this severe complication seems to increase with the number of doses administered.
ConclusionNatalizumab has a favourable risk-benefit ratio in the treatment of relapsing-remitting multiple sclerosis. However, because of the potential risk of progressive multifocal leukoencephalopathy, patients must be carefully selected and specific protocols must be followed during the drug's administration.
Keywords:
Multiple sclerosis
Natalizumab
Monoclonal antibody
Clinical trial
Progressive multifocal leukoencephalopathy
Resumen
Introducción
Natalizumab es un anticuerpo monoclonal inhibidor de la migración leucocitaria a través de la barrera hematoencefálica, autorizado para el tratamiento de la esclerosis múltiple remitente-recurrente.
ObjetivoRealizar una revisión y actualización de los aspectos farmacológicos y terapéuticos de natalizumab, con especial énfasis en los datos de eficacia, efectividad y seguridad publicados más recientemente.
DesarrolloVarios ensayos clínicos aleatorizados en pacientes con formas recurrentes de esclerosis múltiple han demostrado que natalizumab reduce considerablemente la actividad clínica y radiológica de la enfermedad. El análisis post hoc de ensayos clínicos fase III y los resultados de estudios observacionales postautorización indican que natalizumab incrementa significativamente la proporción de pacientes con respuesta clínica y radiológica completa, y que es eficaz en aquellos con formas muy activas de esclerosis múltiple y con respuesta subóptima a otras terapias. Al igual que otros anticuerpos monoclonales, natalizumab puede causar reacciones de hipersensibilidad, siendo graves en el 1% de los pacientes. Otros efectos adversos de natalizumab son en general leves o poco frecuentes. No obstante, se han detectado varios casos de leucoencefalopatía multifocal progresiva en pacientes tratados con natalizumab en monoterapia. El riesgo de esta grave complicación parece incrementarse con el número de dosis recibidas.
ConclusiónNatalizumab ha demostrado una relación beneficio-riesgo favorable en el tratamiento de la esclerosis múltiple remitente-recurrente. El riesgo potencial de leucoencefalopatía multifocal progresiva, sin embargo, obliga a la selección cuidadosa de los pacientes y a seguir protocolos de actuación específicos durante su administración.
Palabras clave:
Esclerosis múltiple
Natalizumab
Anticuerpo monoclonal
Ensayo clínico
Leucoencefalopatía multifocal progresiva
El Texto completo está disponible en PDF
References
[1.]
A. Compston, A. Coles.
Multiple sclerosis.
Lancet, 359 (2002), pp. 1221-1231
[2.]
M. Pugliatti, G. Rosati, H. Carton, T. Riise, J. Drulovic, L. Vécsei, et al.
The epidemiology of multiple sclerosis in Europe.
Eur J Neurol, 13 (2006), pp. 700-722
[3.]
O.H. Kantarci.
Genetics and natural history of multiple sclerosis.
Semin Neurol, 28 (2008), pp. 7-16
[4.]
B. Hemmer, H.P. Hartung.
Toward the development of rational therapies in multiple sclerosis: what is on the horizon?.
Ann Neurol, 62 (2007), pp. 314-326
[5.]
A. Compston, A. Coles.
Multiple sclerosis.
Lancet, 372 (2008), pp. 1502-1517
[6.]
U.H. Von Andrian, B. Engelhardt.
Alpha4 integrins as therapeutic targets in autoimmune disease.
N Engl J Med, 348 (2003), pp. 68-72
[7.]
G.P. Rice, H.P. Hartung, P.A. Calabresi.
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
Neurology, 64 (2005), pp. 1336-1342
[8.]
A. Horga, J.F. Horga de la Parte.
Natalizumab en el tratamiento de la esclerosis múltiple.
Rev Neurol, 45 (2007), pp. 293-303
[9.]
M. Del Pilar Martin, P.D. Cravens, R. Winger, E.M. Frohman, M.K. Racke, T.N. Eagar, et al.
Decrease in the numbers of dendritic cells and CD4+ Tcells in cerebral perivascular spaces due to natalizumab.
Arch Neurol, 65 (2008), pp. 1596-1603
[10.]
W.A. Sheremata, T.L. Vollmer, L.A. Stone, A.J. Willmer-Hulme, M. Koller.
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
Neurology, 52 (1999), pp. 1072-1074
[11.]
M. Hutchinson, Natalizumab.
A new treatment for relapsing remitting multiple sclerosis.
Ther Clin Risk Manag, 3 (2007), pp. 259-268
[12.]
EMEA. EPARs for authorised medicinal products for human use. Scientific discussion. Tysabri [accessed 2010 Feb 1]. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/H-603-en6.pdf.
[13.]
P.W. O’Connor, A. Goodman, A.J. Willmer-Hulme, M.A. Libonati, L. Metz, R.S. Murray, et al.
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
Neurology, 62 (2004), pp. 2038-2043
[14.]
B.O. Khatri, S. Man, G. Giovannoni, A.P. Koo, J.C. Lee, B. Tucky, et al.
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.
Neurology, 72 (2009), pp. 402-409
[15.]
B.V. Sweet.
Natalizumab update.
Am J Health Syst Pharm, 64 (2007), pp. 705-716
[16.]
L. Kappos, D. Bates, H.P. Hartung, E. Havrdova, D. Miller, C.H. Polman, et al.
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
Lancet Neurol, 6 (2007), pp. 431-441
[17.]
N. Tubridy, P.O. Behan, R. Capildeo, A. Chaudhuri, R. Forbes, C.P. Hawkins, et al.
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
Neurology, 53 (1999), pp. 466-472
[18.]
D.H. Miller, O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G.P. Rice, M.A. Libonati, et al.
A controlled trial of natalizumab for relapsing multiple sclerosis.
N Engl J Med, 348 (2003), pp. 15-23
[19.]
A.D. Goodman, H. Rossman, A. Bar-Or, A. Miller, D.H. Miller, K. Schmierer, et al.
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.
Neurology, 72 (2009), pp. 806-812
[20.]
C.H. Polman, P.W. O’Connor, E. Havrdova, M. Hutchinson, L. Kappos, D.H. Miller, et al.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
N Engl J Med, 354 (2006), pp. 899-910
[21.]
R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, E.W. Radue, et al.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
N Engl J Med, 354 (2006), pp. 911-923
[22.]
D.H. Miller, D. Soon, K.T. Fernando, D.G. MacManus, G.J. Barker, T.A. Yousry, et al.
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Neurology, 68 (2007), pp. 1390-1401
[23.]
E. Havrdova, S. Galetta, M. Hutchinson, D. Stefoski, D. Bates, C.H. Polman, et al.
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Lancet Neurol, 8 (2009), pp. 254-260
[24.]
M. Hutchinson, L. Kappos, P.A. Calabresi, C. Confavreux, G. Giovannoni, S.L. Galetta, et al.
The efficacy of natalizumab in patients whaith relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
J Neurol, 256 (2009), pp. 405-415
[25.]
L.J. Balcer, S.L. Galetta, P.A. Calabresi, C. Confavreux, G. Giovannoni, E. Havrdova, et al.
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Neurology, 68 (2007), pp. 1299-1304
[26.]
R.A. Rudick, D. Miller, S. Hass, M. Hutchinson, P.A. Calabresi, C. Confavreux, et al.
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Ann Neurol, 62 (2007), pp. 335-346
[27.]
A.B. Oturai, N. Koch-Henriksen, T. Petersen, P.E. Jensen, F. Sellebjerg, P.S. Sorensen.
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.
Eur J Neurol, 16 (2009), pp. 420-423
[28.]
O. Outteryck, J.C. Ongagna, H. Zéphir, M.C. Fleury, A. Lacour, F. Blanc, et al.
Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.
J Neurol, 257 (2010), pp. 207-211
[29.]
N. Putzki, O. Yaldizli, M. Maurer, S. Cursiefen, S. Kuckert, C. Klawe, et al.
Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Eur J Neurol, 17 (2009), pp. 31-37
[30.]
G. Tedeschi, M.P. Amato, R. D’Alessandro, F. Drago, C. Milanese, P. Popoli, et al.
The pharmacovigilance program on natalizumab in Italy: 2 years of experience.
Neurol Sci, 30 (2009), pp. S163-S165
[31.]
N. Putzki, O. Yaldizli, R. Buhler, G. Schwegler, D. Curtius, B. Tettenborn.
Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
Eur Neurol, 63 (2010), pp. 101-106
[32.]
P.A. Calabresi, G. Giovannoni, C. Confavreux, S.L. Galetta, E. Havrdova, M. Hutchinson, et al.
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Neurology, 69 (2007), pp. 1391-1403
[33.]
EMEA. EPARs for authorised medicinal products for human use. Product information. Tysabri [accessed 2010 Feb 1]. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/emea-combined-h603en.pdf.
[34.]
J.T. Phillips, P.W. O’Connor, E. Havrdova, M. Hutchinson, L. Kappos, D.H. Miller, et al.
Infusion-related hypersensitivity reactions during natalizumab treatment.
Neurology, 67 (2006), pp. 1717-1718
[35.]
M. Krumbholz, H. Pellkofer, R. Gold, L.A. Hoffmann, R. Hohlfeld, T. Kumpfel.
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies.
Arch Neurol, 64 (2007), pp. 1331-1333
[36.]
K. Hellwig, S. Schimrigk, M. Fischer, A. Haghikia, T. Müller, A. Chan, et al.
Allergic and nonallergic delayed infusion reactions during natalizumab therapy.
Arch Neurol, 65 (2008), pp. 648-656
[37.]
V.I. Leussink, H.C. Lehmann, H.P. Hartung, R. Gold, B.C. Kieseier.
Type III systemic allergic reaction to natalizumab.
Arch Neurol, 65 (2008), pp. 851-852
[38.]
B.A. Brown.
Natalizumab in the treatment of multiple sclerosis.
Ther Clin Risk Manag, 5 (2009), pp. 585-594
[39.]
EMEA. EMEA/CHMP/145908/2008. Questions and answers on Tysabri liver injury [accessed 2010 Feb 1]. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/Q&A_Tysabri_14590808en.pdf.
[40.]
J.T. Mullen, T.K. Vartanian, M.B. Atkins.
Melanoma complicating treatment with natalizumab for multiple sclerosis.
N Engl J Med, 358 (2008), pp. 647-648
[41.]
A. Schweikert, M. Kremer, F. Ringel, T. Liebig, J. Duyster, O. Stüve, et al.
Primary central nervous system lymphoma in a patient treated with natalizumab.
Ann Neurol, 66 (2009), pp. 403-406
[42.]
J.C. Álvarez-Cermeño, M. García-Cosío, J. Pérez de Oteyza, T. Gasalla González, L.M. Villar Guimerans, J. Masjuán Vallejo.
Linfoma cerebral primario y tratamiento con natalizumab [abstract].
Neurología, 23 (2008), pp. 34-35
[43.]
C. Zecca, F. Nessi, E. Bernasconi, C. Gobbi.
Ocular toxoplasmosis during natalizumab treatment.
Neurology, 73 (2009), pp. 1418-1419
[44.]
S. Gutwinski, S. Erbe, C. Munch, O. Janke, U. Muller, J. Haas.
Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis.
Neurology, 74 (2010), pp. 521-523
[45.]
A. Langer-Gould, S.W. Atlas, A.J. Green, A.W. Bollen, D. Pelletier.
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
N Engl J Med, 353 (2005), pp. 375-381
[46.]
B.K. Kleinschmidt-DeMasters, K.L. Tyler.
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
N Engl J Med, 353 (2005), pp. 369-374
[47.]
G. Van Assche, M. Van Ranst, R. Sciot, B. Dubois, S. Vermeire, M. Noman, et al.
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
N Engl J Med, 353 (2005), pp. 362-368
[48.]
A. Chaudhuri.
Lessons for clinical trials from natalizumab in multiple sclerosis.
BMJ, 332 (2006), pp. 416-419
[49.]
T.A. Yousry, E.O. Major, C. Ryschkewitsch, G. Fahle, S. Fischer, J. Hou, et al.
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
N Engl J Med, 354 (2006), pp. 924-933
[50.]
AEMPS. Nota informativa. Natalizumab (Tysabri®) y leucoencefalopatía multifocal progresiva: actualización de la información [accessed 2010 Feb 1]. Available at: http://www.aemps.es/actividad/alertas/usoHumano/seguridad/2010/NI_2010-02_natalizumab_tysabri.htm.
[51.]
FDA. Drug Safety Communication: risk of progressive multifocal leukoencephalopathy (LMP) with the use of Tysabri (natalizumab) [accessed 2010 Feb 1]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm.
[52.]
M. Jiang, J.R. Abend, S.F. Johnson, M.J. Imperiale.
The role of polyomaviruses in human disease.
Virology, 384 (2009), pp. 266-273
[53.]
K.R. Carson, D. Focosi, E.O. Major, M. Petrini, E.A. Richey, D.P. West, et al.
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Lancet Oncol, 10 (2009), pp. 816-824
[54.]
I.J. Koralnik.
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?.
Ann Neurol, 60 (2006), pp. 162-173
[55.]
G. Pérez-Liz, L. Del Valle, A. Gentilella, S. Croul, K. Khalili.
Detection of JC virus DNA fragments but not proteins in normal brain tissue.
Ann Neurol, 64 (2008), pp. 379-387
[56.]
T. Weber.
Progressive multifocal leukoencephalopathy.
Neurol Clin, 26 (2008), pp. 833-854
[57.]
S.R. Sunyaev, A. Lugovskoy, K. Simon, L. Gorelik.
Adaptive mutations in the JCvirus protein capsid are associated with progressive multifocal leukoencephalopathy (PML).
PLoS Genet, 5 (2009), pp. e1000368
[58.]
A.J. Aksamit.
Review of progressive multifocal leukoencephalopathy and natalizumab.
Neurologist, 12 (2006), pp. 293-298
[59.]
SEN. Información para el médico y directrices para el manejo de pacientes con esclerosis múltiple en tratamiento con natalizumab. 3rd ed [accessed 2010 Feb 1]. Available at: http://www.sen.es/neuro/aut_pdf.php?path=pdf/2008/&fichero=natalizumab_3ed.pdf.
[60.]
O. Stüve, C.M. Marra, K.R. Jerome, L. Cook, P.D. Cravens, S. Cepok, et al.
Immune surveillance in multiple sclerosis patients treated with natalizumab.
Ann Neurol, 59 (2006), pp. 743-747
[61.]
M. Krumbholz, I. Meinl, T. Kumpfel, R. Hohlfeld, E. Meinl.
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
Neurology, 71 (2008), pp. 1350-1354
[62.]
F. Zohren, D. Toutzaris, V. Klarner, H.P. Hartung, B. Kieseier, R. Haas.
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.
Blood, 111 (2008), pp. 3893-3895
[63.]
H. Bonig, A. Wundes, K.H. Chang, S. Lucas, T. Papayannopoulou.
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.
Blood, 111 (2008), pp. 3439-3441
[64.]
B.F. Sabath, E.O. Major.
Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy.
J Infect Dis, 186 (2002), pp. S180-S186
[65.]
M.C. Monaco, W.J. Atwood, M. Gravell, C.S. Tornatore, E.O. Major.
JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency.
J Virol, 70 (1996), pp. 1012-7004
[66.]
H.P. Hartung.
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.
Lancet Neurol, 8 (2009), pp. 28-31
[67.]
C. Tornatore, D.B. Clifford.
Clinical vigilance for progressive multifocal leukoencephalopathy in the context of natalizumab use.
Mult Scler, 15 (2009), pp. S16-S25
[68.]
R.E. Bartt.
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Curr Opin Neurol, 19 (2006), pp. 341-349
[69.]
R.A. Rudick, M.A. Panzara.
Natalizumab for the treatment of relapsing multiple sclerosis.
Biologics, 2 (2008), pp. 189-199
[70.]
W. Wenning, A. Haghikia, J. Laubenberger, D.B. Clifford, P.F. Behrens, A. Chan, et al.
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
N Engl J Med, 361 (2009), pp. 1075-1080
[71.]
K. Tan, R. Roda, L. Ostrow, J. McArthur, A. Nath.
PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids.
Neurology, 72 (2009), pp. 1458-1464
[72.]
O. Stüve, P.D. Cravens, E.M. Frohman, J.T. Phillips, G.M. Remington, G. Von Geldern, et al.
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
Neurology, 72 (2009), pp. 396-401
[73.]
P. O’Connor, A. Goodman, L. Kappos, F.D. Lublin, D.H. Miller, C.H. Polman, et al.
Return of disease activity after cessation of natalizumab therapy in patients with multiple sclerosis (P793).
Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, pp. 2010
[74.]
M.M. Vellinga, J.A. Castelijns, F. Barkhof, B.M.J. Uitdejaag, C.H. Polman.
Postwithdrawal rebound increase in T2 lesional activity in natalizumab treated MS patients.
Neurology, 70 (2008), pp. 1150-1151
[75.]
N. Schiess, P.A. Calabresi.
Natalizumab: bound to rebound?.
Neurology, 72 (2009), pp. 392-393
[76.]
J. Perumal, S. Hreha, F. Bao, I. Zak, C. Caon, A. Tselis, et al.
Post-natalizumab associated rebound or CNS immune reconstitution syndrome: clinical and MRI findings (P418).
Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, pp. 2010
Copyright © 2011. Sociedad Española de Neurología
